The mission of the Division of Infectious Disease and International Medicine is to be an internationally outstanding academic center. Our faculty members conduct research, analyze policy, deliver clinical care, and provide specialized training to healthcare providers locally, nationally and internationally. Our goal is to be a resource for infectious disease identification, prevention and treatment issues, including bioterrorism and the emergence of new pathogens.
Welcome Dr. Eloho Ajayi as the inaugural Moffitt Cancer Center Transplant Infectious Diseases Fellow FY 2021!
Dr. Ajayi graduated from the University of Lagos, College of Medicine in Nigeria prior to doing an Internal Medicine Residency at Abington-Jefferson Health, Abington, Pennsylvania. Subsequently, Dr. she completed an Adult Infectious Diseases fellowship at University of Cincinnati Medical Center. While in Ohio, she placed second in the Infectious Diseases Society of OH Annual Fellows’ Meeting 2021. She also was the recipient of one of the 2020 IDWeek Trainee Awards. Dr. Ajayi intends on continuing her research interests at Moffitt with focus on fungal infections in the immunosuppressed, especially related to the use of terbinafine as a possible treatment modality.
Dr. Ajayi will be spending 10 months of her 1-year fellowship at Moffitt Cancer Center seeing bone marrow transplant and immunotherapy patients as well as 2 months at Tampa General Hospital focusing on solid organ transplant related infections.
View Dr. Ajayi’s CV here.
Please help us welcome Guy Handley, MD to the Division of Infectious Disease and International Medicine. Dr. Handley recently completed his ID Fellowship (Immunocompromised Track) at McGovern Medical School UT Health/MD Anderson Cancer Center in Houston, TX.
Dr. Handley is originally from Birmingham, Alabama and completed his MD at the University of Alabama. He finished his Internal Medicine Residency at Ochsner Clinical Foundation in New Orleans and an additional year as Chief Medical Resident. He is certified in the American Board of Internal Medicine and is a member of the Infectious Diseases Society of America, the American Society of Transplantation and the American Medical Association. His research interests include epidemiologic, treatment, and outcomes-based research related to infections in immuno-compromised hosts, focusing on patients who have received stem cell or solid organ transplantation. During fellowship, his research was dedicated to viral central nervous system infections including human herpesvirus 6 and cytomegalovirus.
Dr. Handley will join the teaching team at Tampa General Hospital and Moffitt Cancer Center.
On Thursday, August 5, 2021, Florida Governor Ron DeSantis visited Tampa General Hospital in response to the surge in COVID-19 cases and hospitalizations in the Tampa area and across the state. Gov. DeSantis met with John Couris, President and CEO of TGH, Dr. Charles Lockwood, Dean of USF Morsani College of Medicine and Dr. Kami Kim, Director of the Division of Infectious Disease and International Medicine. They discussed the current surge and state of the pandemic as well as the use of monoclonal antibody treatments to decrease severity of illness in those recently diagnosed with COVID-19.
The monoclonal antibody treatment is given through an IV and neutralizes the virus, shortening the duration of symptoms. It is most effective if given within 7 days of the onset of symptoms. In a press conference following the meeting, Dr. Kim reported that USF/TGH has treated over 1,600 patients with the an monoclonal antibodies thus far.
To see the full press conference, click here.
1 Tampa General Circle Rm G323
Tampa, FL 33606